Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035 [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is rising. Key players like Bristol-Myers Squibb and Novartis are leading R&D efforts. The market's growth is strongest in North America and Asia-Pacific, driven by healthcare advancements and increasing awareness. Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The "Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The global acute lymphocytic leukemia market is poised for significant growth from 2025 to 2035, driven by advancements in treatment options, particularly in chemotherapy, targeted therapies, and immunotherapy. ALL is a rare but aggressive cancer of the blood and bone marrow, predominantly aff
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook? [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications [Yahoo! Finance]Yahoo! Finance
- How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website